Clinical trials: GLP-1
Diabetes Type 1
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
The goal of this clinical trial is to learn if Empagliflozin and Semaglutide, individually and combined, added to Automated Insulin Delivery (AID) works to improve time-in-range in adults living with Type 1 Diabetes.
- Trial name
- SEMPA (NCT06894784)
- Testing
- Intervention Period 1: Semaglutide + Empagliflozin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Insulin Resistance
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
- Trial name
- LVKGR (NCT02518932)
- Testing
- Last 5 amino acids of GLP-1
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Elahi, Dariush, PhD
Diabetes Mellitus
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.
- Trial name
- NCT01777282
- Testing
- Albiglutide, Sulfonylurea, Biguanide
- Where
- 49 sites in Japan
- Volunteers
- 374 people
- Sponsor
- GlaxoSmithKline
Adults, GLP-1
Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.
This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.
- Trial name
- NCT07209046
- Testing
- UltraFlora® Triplebiotic
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Sexual Desire
Effects of Glucagon-like-Peptide-1 Analogues on Sexuality
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel…
- Trial name
- Desire PLUS (NCT05598008)
- Where
- Switzerland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
Gastrointestinal Symptoms, Weight Loss
A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications
The objective of this study is to assess self-reported gastrointestinal (GI) responses to three snack bars containing fiber/fiber blends vs. a control snack bar for 7 days each in adults using GLP-1 agonists.
- Conditions
- Gastrointestinal Symptoms, Weight Loss, GLP-1
- Trial name
- NCT07012317
- Testing
- High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
Adolescence Obesity
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
This is a Phase Ib, randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Efsubaglutide Alfa Injection following multiple-dose…
- Trial name
- NCT07693426
- Testing
- Efsubaglutide Alfa 5 mg QW, Efsubaglutide Alfa 10 mg QW, Efsubaglutide Alfa 20 mg QW
- Where
- 5 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Healthy Volunteers (HV)
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of…
- Trial name
- NCT07550621
- Testing
- MDR-001, Rifampin, Itraconazole
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Craniopharyngiomas, Hypothalamic Obesity
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
This hypothalamic obesity is associated with serious metabolic and psychosocial consequences. The purpose of the study is to compare the change of body weight after 6 months treatment with a lifestyle intervention + exenatide…
- Trial name
- CRANIOEXE (NCT02860923)
- Testing
- Exenatide
- Where
- 11 sites in France
- Volunteers
- 42 people
- Sponsor
- University Hospital, Bordeaux
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety.
- Trial name
- UNISHAPE-OSA-1 (NCT07767942)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Polycystic Ovary Syndrome, Obesity
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin…
- Trial name
- NCT02635386
- Testing
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Woman's
GLP-1, Gut Microbiota
Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1
Recently, it has been proposed that the consumption of non-nutritive sweeteners, including sucralose, it's not harmless and is related with metabolic effects.
- Conditions
- GLP-1, Gut Microbiota, Insulin Resistance
- Trial name
- NCT06094894
- Testing
- sucralose
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, PreDiabetes
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
This study is conducted to examine GLP-1, insulin resistance and insulin sensitivity portfolio in Malay, Chinese and Indian populations in Malaysia and to study the effect of DPPIV inhibitor in T2DM patients with different…
- Trial name
- GLP-1 (NCT03659461)
- Testing
- Sitagliptin
- Where
- Malaysia
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Type-1 Diabetes Mellitus
Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus
study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.
- Trial name
- NCT00603031
- Testing
- glucagon like peptide -1, NaCl, glucose dependent insulinotropic polypeptide
- Where
- Denmark
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Gastric Bypass Surgery, Obesity
Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery
Analyze the effect of meal pattern (meal number, frequency, and form) on satiety, gut peptides, insulin, and glucose levels in individuals before and 12-15 months after gastric bypass surgery (GBP).
- Trial name
- NCT01938469
- Testing
- Liquid Meal, Solid Meal
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Diabetes, Heart Failure
The Effects of Neprilysin on Glucagon-like Peptide-1
In the current study we wish to investigate the effects on glucagon-like peptide-1 (GLP-1) of a neprilysin inhibitor
- Trial name
- NEP (NCT03717688)
- Testing
- Entresto, Sitagliptin 100mg
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Obesity, Aging
Semaglutide Use in Elderly Obese Patients
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly…
- Trial name
- NCT05302596
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo